We can't find the internet
Attempting to reconnect
17994.1 PFLS-LS
Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma
Résumé
Anti-Fibroblast Activation Protein immunotherapy to treat pancreatic ductal adenocarcinoma
Textes supplémentaires
Abstract
More than 300¿000 patients are diagnosed with pancreatic ductal adenocarcinoma (PDA) each year with a median survival of only 2-17 months. 82C2 is a novel human derived monoclonal antibody with proven efficacy in mouse carcinoma models, with potential to prolong survival for PDA patients with improved efficacy compared to current standard of care. This CTI project application seeks support to advance 82C2 into clinical trials to treat PDA patients by 2019.
Participants
Chad Brokopp
Wirtschaftspartner
Mabimmune Diagnostics AG Chad Brokopp Wagistrasse 13 8952 Schlieren ZH CH
Simon Hoerstrup
Kontaktperson
Simon_Philipp.Hoerstrup@usz.ch
Universität Zürich Simon Hoerstrup Rämistrasse 100 8091 Zürich ZH CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2015-07-31
- Date de fin
- 2017-10-31
- Coûts totaux approuvés
- CHF 671174.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T490 Biotechnology 100.0%